Innate Pharma Reports Third-Quarter 2026 Business Update
Innate Pharma said Phase 1 dose-escalation data for its Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18.
Innate Pharma said Phase 1 dose-escalation data for its Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18.